The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors

Stephen Nicholls

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: To review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice. Recent Findings: Despite widespread use of statins for lipid lowering, many patients at high cardiovascular risk continue to demonstrate unsatisfactory cholesterol levels and experience clinical events. This highlights the ongoing need to develop additional strategies to achieve more effective risk reduction in a greater number of patients. Proprotein convertase subtilisin kexin type 9 (PCSK9) plays an important role in the regulation of low-density lipoprotein metabolism. Inhibitory approaches that reduce PCSK9 activity have been demonstrated to produce substantive reductions in LDL cholesterol levels, when administered as either monotherapy or in addition to statin therapy. More recently, PCSK9 monoclonal antibodies have been reported to reduce cardiovascular event rates in large scale clinical trials. Summary: Increasing evidence suggests that PCSK9 inhibitors can produce effective lipid lowering in high risk patients. Ongoing work will identify those patients most likely to derive cost effective risk reduction with their use.

LanguageEnglish
Article number18
JournalCurrent Cardiology Reports
Volume21
Issue number4
DOIs
Publication statusPublished - 1 Apr 2019

Keywords

  • Cardiovascular risk
  • Clinical trials
  • Lipids
  • PCSK9

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{b4f436677ee64f8bab3945d747f53e24,
title = "The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors",
abstract = "Purpose of Review: To review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice. Recent Findings: Despite widespread use of statins for lipid lowering, many patients at high cardiovascular risk continue to demonstrate unsatisfactory cholesterol levels and experience clinical events. This highlights the ongoing need to develop additional strategies to achieve more effective risk reduction in a greater number of patients. Proprotein convertase subtilisin kexin type 9 (PCSK9) plays an important role in the regulation of low-density lipoprotein metabolism. Inhibitory approaches that reduce PCSK9 activity have been demonstrated to produce substantive reductions in LDL cholesterol levels, when administered as either monotherapy or in addition to statin therapy. More recently, PCSK9 monoclonal antibodies have been reported to reduce cardiovascular event rates in large scale clinical trials. Summary: Increasing evidence suggests that PCSK9 inhibitors can produce effective lipid lowering in high risk patients. Ongoing work will identify those patients most likely to derive cost effective risk reduction with their use.",
keywords = "Cardiovascular risk, Clinical trials, Lipids, PCSK9",
author = "Stephen Nicholls",
year = "2019",
month = "4",
day = "1",
doi = "10.1007/s11886-019-1103-2",
language = "English",
volume = "21",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors. / Nicholls, Stephen.

In: Current Cardiology Reports, Vol. 21, No. 4, 18, 01.04.2019.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The New Face of Hyperlipidemia and the Role of PCSK9 Inhibitors

AU - Nicholls, Stephen

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Purpose of Review: To review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice. Recent Findings: Despite widespread use of statins for lipid lowering, many patients at high cardiovascular risk continue to demonstrate unsatisfactory cholesterol levels and experience clinical events. This highlights the ongoing need to develop additional strategies to achieve more effective risk reduction in a greater number of patients. Proprotein convertase subtilisin kexin type 9 (PCSK9) plays an important role in the regulation of low-density lipoprotein metabolism. Inhibitory approaches that reduce PCSK9 activity have been demonstrated to produce substantive reductions in LDL cholesterol levels, when administered as either monotherapy or in addition to statin therapy. More recently, PCSK9 monoclonal antibodies have been reported to reduce cardiovascular event rates in large scale clinical trials. Summary: Increasing evidence suggests that PCSK9 inhibitors can produce effective lipid lowering in high risk patients. Ongoing work will identify those patients most likely to derive cost effective risk reduction with their use.

AB - Purpose of Review: To review the clinical rationale for use of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in clinical practice. Recent Findings: Despite widespread use of statins for lipid lowering, many patients at high cardiovascular risk continue to demonstrate unsatisfactory cholesterol levels and experience clinical events. This highlights the ongoing need to develop additional strategies to achieve more effective risk reduction in a greater number of patients. Proprotein convertase subtilisin kexin type 9 (PCSK9) plays an important role in the regulation of low-density lipoprotein metabolism. Inhibitory approaches that reduce PCSK9 activity have been demonstrated to produce substantive reductions in LDL cholesterol levels, when administered as either monotherapy or in addition to statin therapy. More recently, PCSK9 monoclonal antibodies have been reported to reduce cardiovascular event rates in large scale clinical trials. Summary: Increasing evidence suggests that PCSK9 inhibitors can produce effective lipid lowering in high risk patients. Ongoing work will identify those patients most likely to derive cost effective risk reduction with their use.

KW - Cardiovascular risk

KW - Clinical trials

KW - Lipids

KW - PCSK9

UR - http://www.scopus.com/inward/record.url?scp=85062426419&partnerID=8YFLogxK

U2 - 10.1007/s11886-019-1103-2

DO - 10.1007/s11886-019-1103-2

M3 - Review article

VL - 21

JO - Current Cardiology Reports

T2 - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

M1 - 18

ER -